Loading…
Employees: 40
Size Zura Bio (ZURA) is a United States Health Care company (Biotechnology) with a market value of $394M, the 2870th largest of 3,117 United States companies the cockpit tracks. Shares closed at $4.09 on 6 Nov 2026.
Performance Over six months the shares fell 14.6%, against -32.8% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$67,000 | -$49,000 | -$9,000 | $0 | $0 |
| EBITDA | -$102M | -$75.2M | -$55.2M | -$62.6M | -$28.5M |
| Net income | -$122M | -$99.4M | -$45.4M | -$60.4M | -$27.0M |
| Free cash flow | -$81.7M | -$64.9M | -$28.2M | -$15.1M | -$1.20M |
| Capital expenditure | $90,000 | $113,000 | $5.08M | $8.00M | $12.0M |
| Total debt | $0 | $0 | $0 | $0 | $20.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZURA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.0% | -13.4% | 3rd highest of 21 |
| 6-month return | -14.6% | -32.8% | 4th highest of 21 |
| Distance from 52-week high | -45.0% | -47.4% | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | 3,686.9× | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | 0.9× | -15.8% | +197.3% |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | 2.4× | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 1.6× | 43.0% | +8.9% |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | 0.7× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 2.5× | -20.2% | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 1.8× | 4.1% | +6.5% |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | 775.0× | n/a | n/a |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | 23.3× | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 4.2× | 53.3% | +37.6% |